TLSI ▲ +18.5% - TriSalus Life Sciences, Inc. $TLSI TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization TriSalus Life Sciences gained 18.5% after announcing FDA clearance for TriNav® Advance, an addition to its pressure-enabled drug delivery portfolio designed for liver embolization procedures. The clearance expands the company's offerings in interventional oncology, a key growth area, driving investor optimism about the product's commercial potential. 22-SEP-2026 04:19 PM ET